LLY - Eli Lilly and Co
A pharmaceutical giant riding the GLP-1 wave with blockbuster drugs Mounjaro and Zepbound for diabetes and obesity, transforming it into one of the most valuable companies on earth.
Finlify Score
66.7 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$1154.97
-4.55%
52W Range
$623.78 - $1249.45
Market Cap
$1.1T
-4.5%Compared to previous day
2026 Q1 Revenue
$19.8B
+2.6%Changes from last reporting quarter
2026 Q1 EPS
$8.00
Diluted shares
Analyst Rating
38 analysts in latest ratings feed
RSI
43.5
40-70 moderate
2Y Range Position
85%
-7.6% from high / +85.2% from low
Beta
0.51
Relative to market benchmark
MACD
-3.43
MACD line 12.66 / signal line 16.09
Fundamental Trend
Growth 77.7Financial Health
Quality 82.0Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
WATCH66.7 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $19.8B+2.6% | $19.3B+9.6% | $17.6B+13.1% | $15.6B+22.2% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | $7.4B+11.4% | $6.6B+18.9% | $5.6B-1.4% | $5.7B+105.1% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
The Finlify signal for LLY is 'WATCH', with an overall Finlify Score of 68.7/100, which appears to reflect a mixed quantitative outlook balancing strong fundamental and financial quality against a lower accumulation/volume score.
Technical
The Relative Strength score of 68.0/100 suggests generally favorable price momentum for LLY, supported by a significant 60-day return of 36.6%. However, the Accumulation / Volume score of 37.3/100 indicates that buying pressure may be less robust. The asset appears to be trading near its 52-week high, at -4.0% distance, with an RSI(14) of 55.2 suggesting a neutral short-term momentum.
Fundamentals
LLY exhibits strong fundamental characteristics, with a Fundamental Trend score of 77.7/100 and a Financial Quality score of 82.0/100, based on its latest financial period ending 2026-03-31. The valuation multiples, such as a P/E of 54.5x and P/S of 17.3x, appear elevated, which may suggest a premium for its strong financial profile. With a Beta of 0.5, the asset tends to be less volatile than the broader market, and it offers a dividend yield of 0.58%.
Macro Context
The current macro environment, characterized by a 10Y Treasury Yield of 4.7% and a positive yield spread of 0.4%, may suggest a normalizing interest rate landscape. While inflation measures like CPI YoY at 3.7% remain above the Federal Reserve's target, LLY's relatively low Beta of 0.5 might indicate some resilience in a potentially higher-rate or moderately inflationary environment.
Key Risks
- Elevated Valuation Multiples: P/E of 54.5x, P/B of 38.3x, and P/S of 17.3x appear high, which could imply significant growth expectations already priced into the stock.
- Upcoming Earnings Event: An upcoming earnings announcement on 2026-08-05 introduces event-specific volatility and potential price sensitivity to results.
- Weaker Accumulation: The Accumulation / Volume score of 37.3/100 suggests that despite recent price gains, the underlying buying interest may not be as strong as other components indicate.